10 Charged in $20 Million Scheme to Sell Black-Market H.I.V. Drugsnews2023-10-21T02:05:57+00:00October 21st, 2023|The New York Times|
PEPFAR Turned the Tide of AIDS and It’s Now at Risknews2023-09-21T19:59:01+00:00September 21st, 2023|The New York Times|
Why One Drug Company Held Back a Better Drugnews2023-09-07T10:00:12+00:00September 7th, 2023|The New York Times|
Expert Panel Recommends New Drugs for HIV Preventionnews2023-08-22T15:55:45+00:00August 22nd, 2023|The New York Times|
How Gilead Profited by Slow-Walking a Promising H.I.V. Therapynews2023-07-22T18:26:55+00:00July 22nd, 2023|The New York Times|
When Politics Saves Lives: a Good-News Storynews2023-06-07T17:50:17+00:00June 7th, 2023|The New York Times|
Gilead Wins Key Patent Rights Suit Over HIV Prevention Drug PrEPnews2023-05-09T17:34:57+00:00May 9th, 2023|The New York Times|
The Only H.I.V. Vaccine in Advanced Trials Has Failed. What Now?news2023-01-18T21:26:06+00:00January 18th, 2023|The New York Times|
How Anthony Fauci Quietly Shocked AIDS Activistsnews2022-12-31T14:00:06+00:00December 31st, 2022|The New York Times|
Un nuevo tratamiento contra el VIH ha probado ser un éxito. ¿Será accesible en África?news2022-09-30T09:00:20+00:00September 30th, 2022|The New York Times|
